Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Hands LEO Dermatology Potential

Executive Summary

AstraZeneca PLC is handing over two pipeline skin disease medicines, tralokinumab and brodalumab, to LEO Pharma for an upfront payment of $115m while it focuses on other key therapy areas. The UK big pharma has also put an end to its license with Valeant Pharmaceuticals for brodalumab in Europe in favor of its new partner.


Related Content

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount
AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead
Executive Interview: Gitte Aabo On Leo Pharma's Innovation Strategy
Asthma Pipeline Pressure For AstraZeneca As STRATOS 1 Fails
Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity
2016 Pharma Dealmaking: Waiting On The High-Value Deals
AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline
AstraZeneca’s Business Development Head Grady Outlines Strategy Mix
AstraZeneca Unburdens Itself Of Brodalumab


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts